Mylan Ireland Ltd Drug Patent Portfolio
Mylan Ireland Ltd owns 1 orange book drug protected by 20 US patents Given below is the list of Mylan Ireland Ltd's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11484531 | Methods for treating chronic obstructive pulmonary disease | 23 Oct, 2039 | Active |
US12048692 | Methods for treating chronic obstructive pulmonary disease | 29 Aug, 2039 | Active |
US8541451 | Crystalline freebase forms of a biphenyl compound | 25 Aug, 2031 | Active |
US10550081 | Crystalline freebase forms of a biphenyl compound | 14 Jul, 2030 | Active |
US11008289 | Crystalline freebase forms of a biphenyl compound | 14 Jul, 2030 | Active |
US11691948 | Crystalline freebase forms of a biphenyl compound | 14 Jul, 2030 | Active |
US11858898 | Crystalline freebase forms of a biphenyl compound | 14 Jul, 2030 | Active |
US9765028 | Crystalline freebase forms of a biphenyl compound | 14 Jul, 2030 | Active |
US7288657 | Biphenyl compounds useful as muscarinic receptor antagonists | 31 Oct, 2028 | Active |
US10106503 | Biphenyl compounds useful as muscarinic receptor antagonists | 10 Mar, 2025 | Active |
US10343995 | Biphenyl compounds useful as muscarinic receptor antagonists | 10 Mar, 2025 | Active |
US11247969 | Biphenyl compounds useful as muscarinic receptor antagonists | 10 Mar, 2025 | Active |
US7491736 | Biphenyl compounds useful as muscarinic receptor antagonists | 10 Mar, 2025 | Active |
US7521041 | Biphenyl compounds useful as muscarinic receptor antagonists | 10 Mar, 2025 | Active |
US7550595 | Biphenyl compounds useful as muscarinic receptor antagonists | 10 Mar, 2025 | Active |
US7585879 | Biphenyl compounds useful as muscarinic receptor antagonists | 10 Mar, 2025 | Active |
US7910608 | Biphenyl compounds useful as muscarinic receptor antagonists | 10 Mar, 2025 | Active |
US8034946 | Biphenyl compounds useful as muscarinic receptor antagonists | 10 Mar, 2025 | Active |
US8053448 | Biphenyl compounds useful as muscarinic receptor antagonists | 10 Mar, 2025 | Active |
US8273894 | Biphenyl compounds useful as muscarinic receptor antagonists | 10 Mar, 2025 | Active |
Latest Legal Activities on Mylan Ireland Ltd's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Mylan Ireland Ltd.
Activity | Date | Patent Number |
---|---|---|
Change in Power of Attorney (May Include Associate POA)
Critical
| 03 May, 2024 | US7585879 |
Email Notification
Critical
| 03 May, 2024 | US7585879 |
Change in Power of Attorney (May Include Associate POA)
Critical
| 25 Apr, 2024 | US7288657 |
Email Notification
Critical
| 25 Apr, 2024 | US7288657 |
Payment of Maintenance Fee, 12th Year, Large Entity | 25 Mar, 2024 | US8273894 |
Notice of Final Determination -Election Required | 22 Mar, 2024 | US7288657 |
Notice of Final Determination -Election Required | 22 Mar, 2024 | US7585879 |
Patent eCofC Notification | 20 Feb, 2024 | US11858898 |
Email Notification
Critical
| 20 Feb, 2024 | US11858898 |
Recordation of Patent eCertificate of Correction | 20 Feb, 2024 | US11858898 |
Mail Patent eCofC Notification | 20 Feb, 2024 | US11858898 |
Post Issue Communication - Certificate of Correction | 31 Jan, 2024 | US11858898 |
Recordation of Patent eGrant | 02 Jan, 2024 | US11858898 |
Patent Issue Date Used in PTA Calculation
Critical
| 02 Jan, 2024 | US11858898 |
Mail Patent eGrant Notification | 02 Jan, 2024 | US11858898 |
Mylan Ireland Ltd's Family Patents
Mylan Ireland Ltd drugs have patent protection in a total of 31 countries. It's US patent count contributes only to 39.8% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Mylan Ireland Ltd Drug List
Given below is the complete list of Mylan Ireland Ltd's drugs and the patents protecting them.
1. Yupelri
Yupelri is protected by 20 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11484531 | Methods for treating chronic obstructive pulmonary disease |
23 Oct, 2039
(15 years from now)
| Active |
US12048692 | Methods for treating chronic obstructive pulmonary disease |
29 Aug, 2039
(14 years from now)
| Active |
US8541451 | Crystalline freebase forms of a biphenyl compound |
25 Aug, 2031
(6 years from now)
| Active |
US10550081 | Crystalline freebase forms of a biphenyl compound |
14 Jul, 2030
(5 years from now)
| Active |
US11008289 | Crystalline freebase forms of a biphenyl compound |
14 Jul, 2030
(5 years from now)
| Active |
US11691948 | Crystalline freebase forms of a biphenyl compound |
14 Jul, 2030
(5 years from now)
| Active |
US11858898 | Crystalline freebase forms of a biphenyl compound |
14 Jul, 2030
(5 years from now)
| Active |
US9765028 | Crystalline freebase forms of a biphenyl compound |
14 Jul, 2030
(5 years from now)
| Active |
US7288657 | Biphenyl compounds useful as muscarinic receptor antagonists |
31 Oct, 2028
(4 years from now)
| Active |
US10106503 | Biphenyl compounds useful as muscarinic receptor antagonists |
10 Mar, 2025
(4 months from now)
| Active |
US10343995 | Biphenyl compounds useful as muscarinic receptor antagonists |
10 Mar, 2025
(4 months from now)
| Active |
US11247969 | Biphenyl compounds useful as muscarinic receptor antagonists |
10 Mar, 2025
(4 months from now)
| Active |
US7491736 | Biphenyl compounds useful as muscarinic receptor antagonists |
10 Mar, 2025
(4 months from now)
| Active |
US7521041 | Biphenyl compounds useful as muscarinic receptor antagonists |
10 Mar, 2025
(4 months from now)
| Active |
US7550595 | Biphenyl compounds useful as muscarinic receptor antagonists |
10 Mar, 2025
(4 months from now)
| Active |
US7585879 | Biphenyl compounds useful as muscarinic receptor antagonists |
10 Mar, 2025
(4 months from now)
| Active |
US7910608 | Biphenyl compounds useful as muscarinic receptor antagonists |
10 Mar, 2025
(4 months from now)
| Active |
US8034946 | Biphenyl compounds useful as muscarinic receptor antagonists |
10 Mar, 2025
(4 months from now)
| Active |
US8053448 | Biphenyl compounds useful as muscarinic receptor antagonists |
10 Mar, 2025
(4 months from now)
| Active |
US8273894 | Biphenyl compounds useful as muscarinic receptor antagonists |
10 Mar, 2025
(4 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Yupelri's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List